

December 21, 2023

## Execution of Share Transfer Agreement on Overseas Joint Venture Subsidiary

Mitsubishi Tanabe Pharma Corporation (Headquarters: Chuo-ku, Osaka; Representative Director: Akihiro Tsujimura; hereinafter, "MTPC"), a member of Mitsubishi Chemical Group, announced that MTPC has recently executed share purchase/transfer agreement with Grand Pharma (China) Co., Ltd. (Head Office: Wuhan, Hubei Province, China; Representative President: Weikun Tang; hereinafter, "Grand Pharma (China)") to transfer its share and interest in Tianjin Tanabe Seiyaku Co., Ltd. (Head Office: Tianjin, China; Chairman: Ping Zhang; hereinafter, "Tianjin Tanabe"), an overseas consolidated subsidiary of MTPC. Tianjin Lisheng Pharmaceutical Co., Ltd. (Head Office: Tianjin, China; Chairman: Ping Zhang; hereinafter, "Tianjin Lisheng"), which jointly owns shares in Tianjin Tanabe, has waived its right to preferentially purchase MTPC's share in Tianjin Tanabe.

### 1. Background to execution of share transfer agreement

Since its establishment in 1993, Tianjin Tanabe has contributed to patients in China through the manufacturing and marketing of high-quality pharmaceutical products for cardiovascular diseases, gastrointestinal diseases and antiallergic diseases. However, considering the recent changes in the business environment in China, MTPC has decided to transfer its share in Tianjin Tanabe to a company with deep knowledge of the Chinese market to lead the further growth and competitiveness of Tianjin Tanabe.

Grand Pharma (China) is a core company of Grand Pharmaceutical Group Limited. Grand Pharma (China) is a pharmaceutical company with strengths in the manufacture and marketing of cardiovascular medicines, etc. and has positioned expansion of its cardiovascular product lineup and improvement of production and supply capacity as one of its business strategies. MTPC firmly believes that Tianjin Tanabe will be able to develop and grow its business with taking advantage of its strengths by becoming a subsidiary of Grand Pharma (China).

### 2. Outline of Tianjin Tanabe

- Corporate name: Tianjin Tanabe Seiyaku Co., Ltd.
- Location: No. 16 MIP Third Road, Micro-Electronics Industrial Park, Tianjin Economic-Technological Development Area, Tianjin, China
- Representatives: Chairman Ping Zhang, President Kazuyuki Shioya
- Registered Capital: US \$16.23 million
- Sales: 402,696,000 RMB (as of 2022)
- Business activities: Manufacturing and marketing of pharmaceutical products
- Number of employees: 384 (as of the end of November 2023)
- Equity holders: MTPC 75.35%, Tianjin Lisheng 24.65%

### 3. Outline of the party to which share transfer agreement has executed

- Corporate name: Grand Pharma (China) Co., Ltd.
- Location: No. 1-6, 23F, Building 1, No. 160 Qiaokou Road, Qiaokou District, Wuhan City, Hubei Province, China
- Representative President: Weikun Tang
- Registered capital: 4,906,230,000 RMB
- Sales: Not disclosed
- Business activities: Manufacturing and marketing of pharmaceutical products
- Number of employees: Not disclosed
- Equity holders: Grand Pharmaceutical Group Limited 99.84%

### 4. Share transfer value

7,364 million Japanese Yen

5. Impact on financial results

MTPC will disclose it accordingly if there is any impact on business results.

*Contact:*

Mitsubishi Chemical Group Corporation  
Corporate Communications Division  
Osaka Corporate Communications Department  
+81-6-6205-5119